Team 2017-12-06T16:51:28+00:00

TEAM

JOHN CASSIDY
Co-Founder & CEO

John has a background in cancer research in both academia (Cancer Research UK, University of Glasgow, and University of Cambridge) and pharma (MedImmune). His PhD at Cambridge University focused on understanding how tumors become resistant to therapy. He also has experience with multiple start-ups.

HARRY CLIFFORD
Co-Founder & Chief Technology Officer

Harry leads the development of CCG’s AI tech, cloud architecture, and tumor analysis pipelines. He has a background in cancer bioinformatics, completing his PhD at Oxford University and first postdoc at Cambridge University with Cancer Research UK. He also brings corporate experience in identifying and developing biomarker-based medical diagnostics.

EVALINE TSAI
Co-Founder & Chief Product Officer

Evaline oversees the design and delivery of services to cancer care providers and biopharmaceutical customers. She holds a BSE in Chemical and Biological Engineering from Princeton University. Evaline has corporate experience in the petrochemical industry as a process engineer at ExxonMobil and consulting experience within the biotech and nonprofit sectors. She has further experience with engineering and biotechnology through her PhD at Cambridge University.

NIRMESH PATEL
Co-Founder & Chief Scientific Officer

Nirmesh spearheads the clinical research and establishes experimental developments at CCG, sitting at the interface between clinical collaborators and the lab. He brings a deep understanding of the clinical applications of cancer biology, with a background in translational cancer medicine and novel therapeutic development through his PhD at King’s College London and the Institute of Cancer Research.

HANNAH THOMPSON
Chief of Staff

Hannah is a translational cancer biologist. She has a pharmacology masters degree which included a year of drug discovery with MedImmune and a PhD on the link between type 2 diabetes and colorectal cancer from QMUL. Hannah is passionate about transforming clinical cancer care and will be using her colorectal cancer expertise to help us deliver our product.

EMIL HEWAGE
Founding Advisor

Emil is a serial entrepreneur and co-founder of Alchera Technologies with an academic background as a PhD researcher in computational neuroscience at the University of Cambridge. He has extensive knowledge in developing and marketing medical devices and has held roles in finance and numerous technology startups.

GEOFFROY DUBOURG-FELONNEAU
Machine Learning Engineer

Geoffroy is an ML and AI lover. He is a full-stack engineer with experience in deep neural networks and cloud computing architecture. He has prior experience in the Silicon Valley start-up scene, and is now turning his attention to revolutionising cancer genomics.

JELMAR QUIST

Bioinformatician

Jelmar has extensive experience working with genetic data through his PhD where he identified and characterised distinctive imprints of breast cancer to understand their use as predictors of drug sensitivity or as surrogate markers of DNA damage response deficiencies. He’s also worked on integrating genomic and transcriptomic data to establish a triple negative breast cancer (TNBC) classification, describe the molecular features of the different TNBC subgroups and ultimately assess their clinical relevance.

NIKITA DESAI

Bioinformatician

Nikita has extensive experience in big data analysis, machine learning, coding and algorithm design. She has a Bachelors in Chemical and Biomedical engineering from University of Toronto, Masters of Science (M.Sc.) in Biochemistry and Bioinformatics from McGill University.

JENNI WESTOBY

Bioinformatics Researcher

Jenni is working on developing our bioinformatics pipeline as part of her PhD in genetics at The University of Cambridge.

JOS VAN DER WESTHUIZEN 
Machine Learning Researcher

Jos is using ML to help us understand the underlying attributes of cancer relapse. Jos has expertise in machine learning through his PhD in deep learning and clinical monitoring where he’s investigating the biological applications, extensions, and visualisations of long short-term memory recurrent neural networks. He has a background in mechatronic engineering and computational neuroscience with a strong interest in entrepreneurship.

FERGAL COTTER

Machine Learning Researcher

Fergal is using ML to understand the attributes underlying cancer relapse. Fergal’s ML experience comes through his PhD in the Signal Processing group at the University of Cambridge, where he is looking at improving the understanding and performance of convolutional neural networks by applying signal processing methods. He has prior industry experience in Automation and Control and likes to spend time outside his PhD looking at applying ML in fun, different and/or useful ways.

Bitnami